WO2015114855A1 - Utilisation d'un inhibiteur de kinésine contenant de la lutéoline ou son glucoside comme principe actif - Google Patents

Utilisation d'un inhibiteur de kinésine contenant de la lutéoline ou son glucoside comme principe actif Download PDF

Info

Publication number
WO2015114855A1
WO2015114855A1 PCT/JP2014/068526 JP2014068526W WO2015114855A1 WO 2015114855 A1 WO2015114855 A1 WO 2015114855A1 JP 2014068526 W JP2014068526 W JP 2014068526W WO 2015114855 A1 WO2015114855 A1 WO 2015114855A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
acid
genus
derivatives
luteolin
Prior art date
Application number
PCT/JP2014/068526
Other languages
English (en)
Japanese (ja)
Inventor
田中　清隆
小島　弘之
有香 河合
Original Assignee
一丸ファルコス株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 一丸ファルコス株式会社 filed Critical 一丸ファルコス株式会社
Publication of WO2015114855A1 publication Critical patent/WO2015114855A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the present invention suppresses kinesin that is useful for promoting the production of melanin pigment and mitigating or suppressing pigmentation caused by various causes including ultraviolet rays, and preventing or ameliorating symptoms associated with physiological aging of skin and photoaging. And various compositions containing a kinesin inhibitor.
  • the main structure of the spindle folds, cilia and flagella formed during cell division consists of bundles of multiple microtubules, which are responsible for movements such as chromosome movement and flagella strikes.
  • Dynein and kinesin are known as motor proteins using microtubules as scaffolds. These are also involved in the intracellular localization of molecules such as proteins and mRNAs, but in this case, the transport from the-end to the + end is antegrade and the transport from the + end to the-end is reversed. Differentiated by sex, both transports are caused by the interaction of the microtubule system with a group of motor proteins present in the cytoplasm. Kinesin is said to play an important role in antegrade transport and dynein in retrograde transport.
  • Kinesin is a group of proteins that are contained in the cytoplasm of eukaryotes and exist widely from yeast to rats and humans. Kinesin mainly has the property of moving along microtubules while hydrolyzing ATP, and plays an important role in intracellular substance transport such as cell division and nerve axon transport.
  • Kinesin is regarded as important for its function in melanocytes, which synthesize melanin pigments that determine skin color. Melanin is produced in vesicles called melanosomes, and kinesin is involved in transporting these melanosomes to keratinocytes. It has been reported that by suppressing the action of kinesin, pigmentation due to ultraviolet rays is suppressed (Hara et al., 2000), suggesting the development of a new whitening agent. (See Non-Patent Document 1, etc.)
  • an object of the present invention is to provide a novel and useful kinesin inhibitor and a composition useful for alleviating and suppressing various pigmentation symptoms including stains and buckwheat.
  • the present inventor has conducted extensive studies on the theme of excellent natural substances that suppress the expression of kinesin.
  • the present inventors have identified a specific substance, luteolin or a glycoside thereof (luteolin-7-O-galactoside, luteolin-7-O-galactoside-4 ′, luteolin-4′-O-glucuronide, luteolin- 5-O-glucuronide, luteolin-7-O-glucuronide, luteolin-4'-O-glucoside, luteolin-7-O-glucoside) Luteolin or its glycoside (Luteolin-7-O-galactoside, luteolin-7-O-galactoside-4 ', luteolin-4'-O-glucuronide, luteolin-5-O-glucuronide, luteolin-7 -O-glucuronide, luteolin-4′-O-glucoside, luteolin-7-O-glucoside) are used as kinesin inhibitors or pigmentation inhibitors containing as active ingredients. Furthermore, the present invention has been completed by providing various compositions (pharmaceutical composition, food / beverage composition, cosmetic
  • Luteolin, luteolin-7-O-galactoside, luteolin-7-O-galactoside-4 ′, luteolin-4′-O-glucuronide, luteolin-5-O-glucuronide, luteolin-7-O-glucuronide, luteolin of the present invention It is a figure which shows the kinesin inhibitory effect of -4'-O-glucoside and luteolin-7-O-glucoside.
  • “Luteoline” used in the present invention is 3 ′, 4 ′, 5,7-tetrahydroxyflavone, chemical formula: C 15 H 10 O 62 , molecular weight: 286.24, and commercially available reagents and plants. A product extracted and purified from the above or a synthetic product can also be used.
  • the luteolin of the present invention or a glycoside thereof is water, methanol, ethanol, propyl alcohol, isopropyl alcohol, butanol, isobutanol and other lower alcohols or hydrous lower alcohols, Propylene glycol, 1,3-butylene glycol, 1,2-butylene glycol, 1,4-butylene glycol, 1,5-pentanediol, 1,2-pentanediol, 1,3-pentanediol, 1,4-pentane Polyhydric alcohols such as diol, 1,3,5-pentanetriol, glycerin, polyethylene glycol (mole)
  • the shape of glucoside, luteolin-7-O-glucoside) may be any shape such as liquid, solid, powder, paste, etc., and an optimal shape can be arbitrarily selected for carrying out the present invention. .
  • the content of (O-glucoside) is not particularly limited as long as it can be confirmed that inhibition of kinesin or inhibition of pigmentation can be confirmed, but generally 0.001 mg / g to 200 mg / g. A range of (the denominator indicates the weight of the preparation) is preferred.
  • the active ingredient can be mixed with a solid or liquid nontoxic pharmaceutical carrier suitable for administration methods such as oral administration, rectal administration and injection, and administered in the form of a conventional pharmaceutical preparation.
  • a solid or liquid nontoxic pharmaceutical carrier suitable for administration methods such as oral administration, rectal administration and injection
  • administration methods such as oral administration, rectal administration and injection
  • preparations include solid preparations such as tablets, granules, powders and capsules, liquid preparations such as solutions, suspensions and emulsions, freeze-dried preparations, and the like. It can be prepared by conventional means.
  • non-toxic pharmaceutical carrier examples include glucose, lactose, sucrose, starch, mannitol, dextrin, fatty acid glyceride, polyethylene glycol, hydroxyethyl starch, ethylene glycol, polyoxyethylene sorbitan fatty acid ester, amino acid, gelatin, Examples include albumin, water, and physiological saline. If necessary, conventional additives such as a stabilizer, a wetting agent, an emulsifier, a binder, and a tonicity agent may be added as appropriate.
  • a food / beverage product composition As a food / beverage product composition, it is eaten as a health food, a health food, a supplement, or a food material as it is or after adding various nutritional components and contained in the food / beverage product.
  • a food / beverage product composition it is eaten as a health food, a health food, a supplement, or a food material as it is or after adding various nutritional components and contained in the food / beverage product.
  • it may be used for edible by using conventional means, and forming into an edible form, for example, granular, granular, tablet, capsule, paste, etc.
  • various foods such as processed marine products such as kamaboko and chikuwa, livestock products such as sausage and ham, Western confectionery, Japanese confectionery, raw noodles, Chinese noodles, boiled noodles, buckwheat noodles, sauce, soy sauce, sauce, Seasonings such as sugar, honey, powdered candy, syrup, etc., spices such as curry powder, mustard powder, pepper powder, jam, marmalade, chocolate spread, pickles, red vegetables, sprinkles, canned and bottled vegetables and fruits Processed vegetables and fruits, dairy products such as cheese, butter, yogurt, miso soup, soup, fruit juice, vegetable juice, whey beverage, soft drink, alcoholic beverages, liquid food, etc. Addition to can be used, also, pet food, can also be used for animals and plants for feed and the like.
  • a cosmetic composition for example, it can be used in various external preparations (including preparations used for animals) in general, specifically, ampoules, capsules, pills, tablets, powders, granules, solids, liquids 1) Pharmaceuticals, 2) Quasi-drugs, 3) Topical or systemic skin cosmetics (eg lotion) , Basic cosmetics such as emulsion, cream, ointment, lotion, oil, pack, facial cleanser and skin cleanser, massage agent, cleansing agent, hair remover, hair remover, shaving treatment, after shave lotion, pre-shave Makeup cosmetics such as lotion, shaving cream, foundation, lipstick, blusher, eye shadow, eyeliner, mascara, perfume, beauty nail, beauty nail enamel, Nail enamel remover, poultice, plaster, tape, sheet, patch, aerosol, etc.), 4) medicinal and / or cosmetic preparations applied to the scalp and hair (eg shampoo, rinse) Hair treatment agents, pre-hair treatment agents, permanent liquids, hair dyes, hair styling agents, hair styling agents, hair
  • the kinesin inhibitor, pigmentation inhibitor of the present invention, and various compositions (pharmaceutical composition, food / beverage composition, cosmetic composition), luteolin of the present invention, which is an essential active ingredient, or a composition thereof.
  • pharmaceutical composition food / beverage composition, cosmetic composition
  • luteolin of the present invention which is an essential active ingredient, or a composition thereof.
  • saccharides it can be produced by arbitrarily selecting and using the components and additives exemplified below within the range that does not impair the effects of the present invention, and it can be added with various functions. It is.
  • the content in the preparation is not particularly limited, but a concentration range of usually 0.0001 to 50% is preferable.
  • Pigmentation inhibitor A pigmentation inhibitor can be added to the present invention.
  • pigmentation inhibitors include p-aminobenzoic acid derivatives, salicylic acid derivatives, benzenesulfonamide derivatives, imidazole derivatives, naphthalene derivatives, hydroxyanthranilic acid or salts thereof, and derivatives thereof, anthranilic acid derivatives, coumarin derivatives, amino acids Derivatives (2-amino-3- [1-carboxyl-2- (1H-imidazol-4-yl) ethyl] aminobutanoic acid, 2-amino-3- [1-carboxyl-2- (1H-imidazole) -4-yl) ethyl] aminobutanoic acid hydrochloride, 2-amino-3- [1-carboxyl-2- (1H-imidazol-4-yl) ethyl] aminobutanoic acid sodium salt, 2-amino-3- [ 1-carboxyl-2- (1
  • Tyrosinase activity inhibitor A tyrosinase activity inhibitor can be added to this invention.
  • tyrosinase activity inhibitors include ascorbic acid or a salt thereof and derivatives thereof (phosphoric acid-magnesium ascorbate, ascorbyl palmitate, ascorbyl dipalmitate, hydroxyprophosphate phosphate ascorbate, 5-o- ⁇ -D-glucopyranosyl-L-ascorbic acid, L-ascorbic acid phosphate sodium salt, L-ascorbic acid phosphate potassium salt, L-ascorbic acid phosphate magnesium salt, L-ascorbic acid phosphate calcium salt, L-ascorbic acid phosphate aluminum salt, L-ascorbic acid sulfate sodium salt, L-ascorbic acid sulfate potassium salt, L-ascorbic acid sulfate magnesium salt, L-ascorbic acid sulfate calcium salt, L-ascorbic acid Sulfur
  • hydroquinone ⁇ -D-ribose hydroquinone ⁇ -D-ribose, hydroquinone ⁇ -L-ribose, hydroquinone ⁇ -L-ribose, hydroquinone ⁇ -D-arabinose, hydroquinone ⁇
  • Five-carbon sugar glycosides such as -D-arabinose, hydroquinone ⁇ -L-arabinose, hydroquinone ⁇ -L-arabinose, hydroquinone ⁇ -D-glucosamine, hydroquinone ⁇ -D-glucosamine, hydroquinone ⁇ -L-glucosamine, hydroquinone ⁇ -Amino sugar glycosides such as L-glucosamine, hydroquinone ⁇ -D-galactosamine, hydroquinone ⁇ -D-galactosamine, hydroquinone ⁇ -L-galactosamine, hydroquinone ⁇ -L-galactosamine, hydroquinone ⁇ -L-
  • Isonitrile antibiotics, orselinic acid derivatives (orceric acid, orthoselic acid ethyl Ester orcinol, p-geranyl orthoselic acid, p-geranyl orthoselic acid ethyl ester geranyl orcinol, p-farnesyl orthoselic acid, p-farnesyl orthoselic acid ethyl ester farnesyl orcinol, p-dodecanyl orthoseric acid, p-dodecanylorceric acid ethyl ester dodecanylorcinol, p-tetradecanylorceric acid, p-tetradecanylorceric acid ethylester tetradecanylorcinol, p-hexadecanylorceric acid, p- Hexadecanylorceric acid ethyl ester Hexadecanylorcinol, p-undecanylorceric acid,
  • melanocyte melanin Production inhibitor can be added to the present invention.
  • melanocyte melanin production inhibitors include lobeline or lobeline derivatives, liquiritin derivatives (such as liquiritin- ⁇ -glucoside, liquiritin- ⁇ -maltoside), phenylchroman derivatives, chromone derivatives (2-butylchromone, 2-pentylchromone, 2 -Heptylchromone, 2-nonylchromone, 2-hexadecylchromone, 2- (1-ethylpentyl) chromone, 2-butyl-7-methoxychromone, 2-pentyl-7-methoxychromone, 2-heptyl-7-methoxychromone , 2-nonyl-7-methoxychromone, 2-pentadecyl-7-methoxychromone, 2- (1-ethylpenty
  • Melanin production promoter A melanin production promoter can be added to the present invention.
  • the melanin production promoter include salicylic acid or a salt thereof and derivatives thereof (salicylic acid glucoside, salicylic acid fatty acid ester, salicylic acid alcohol ether, salicylic acid amides, etc.), salicyl alcohol or a salt thereof and derivatives thereof, apigenin, and amentoflavone.
  • Humectant A humectant can be added to the present invention.
  • moisturizers include gum arabic, benzoin rubber, danmar gum, guaiac oil, Irish moss, karaya gum, tragacanth gum, carob gum, quince seed, agar or its derivatives, casein, glucose, galactose, mannose, xylose, fructose, maltose, iso Maltose, cellobiose, gentiobiose, trehalose, cordierbiose, laminaribiose, nigerose, sambubiose, neohesperidose, apiose, hammamellose, streptose, hydroxystreptose, dihydrostreptose, 2-methylerythrose or derivatives thereof, 2-methylerythrono Lactone, micalose, cladinose, accessose, alkanose, olivomai course, chromose
  • Cell activating agent / metabolic activator A cell activating agent / metabolic activator can be added to the present invention.
  • Specific examples of cell activators and metabolic activators include vitamin A group: retinol or its salts and derivatives thereof (retinyl unsaturated fatty acid esters such as retinyl linoleate, retinyl linolenate, retinyl oleate, retinyl arachidonic acid, etc.) ), Retinal or a salt thereof and derivatives thereof, dehydroretinal or a salt thereof and derivatives thereof, retinoic acid or a salt thereof and derivatives thereof, retinoic acid analogs (4-[[[8- (3,5-dimethylphenyl ) -2-Naphthalenyl] carbonyl] amino] benzoic acid, 4-[[[8- (3-methylphenyl) -2-naphthalenyl) carbonyl] amino] benzoic acid, 4-[[[8-
  • antioxidants include ascorbic acid or a salt thereof and derivatives thereof (phosphoric acid-magnesium ascorbate, ascorbyl palmitate, ascorbyl dipalmitate, ascorbyl hydroxyprophosphate, 5-o- ⁇ -D-glucopyranosyl-L-ascorbic acid, L-ascorbic acid phosphate sodium salt, L-ascorbic acid phosphate potassium salt, L-ascorbic acid phosphate magnesium salt, L-ascorbic acid phosphate calcium salt, L-ascorbic acid phosphate aluminum salt, L-ascorbic acid sulfate sodium salt, L-ascorbic acid sulfate potassium salt, L-ascorbic acid sulfate magnesium salt, L-ascorbic acid sulfate calcium salt, L-ascorbic acid Sulfate ester Nium salt, L-ascorbic acid sodium salt, L-ascorbic acid potassium
  • Active oxygen scavenger / radical scavenger can be added to the present invention.
  • Fat Metabolism Promoter A fat metabolism promoter can be added to the present invention.
  • Specific examples of fat metabolism promoters include phthalazine derivatives (4-ethyl-1- ( ⁇ -hydroxyethylamino) phthalazine, 4-N-propyl-1- ( ⁇ -hydroxyethylamino) phthalazine, 4-N-butyl- 1- ( ⁇ -hydroxyethylamino) phthalazine, 4-N-butyl-1- ( ⁇ -hydroxypropylamino) phthalazine, etc.), xanthine derivatives (theophylline, theobromine, xanthine, aminophylline, choline theophylline, diprofylline, proxyphylline, and octo) Strifeline, etc.), Aotsuki-rafuji (wooden candy) extract, thistle extract, aletia thistle extract, white thistle extract, paddy thistle extract, noel
  • UV protection agent / UV absorption promoter An UV protection agent / UV absorption promoter can be added to the present invention.
  • UV protective agents and UV absorption accelerators include benzophenone derivatives (2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid, 2-hydroxy-4-methoxybenzophenone-5- Sodium sulfonate, dihydroxydimethoxybenzophenone, dihydroxydimethoxybenzophenone sodium sulfonate, 2,4-dihydroxybenzophenone, tetrahydroxybenzophenone, etc.), 1,2-dihydroxy-4- (2-hydroxyethyl) benzene derivatives (1- (2- (4- (3,4-Dihydroxycinnamoyl) -3-rhamnosyl) glucosyl) ethyl-3-hydroxy-4-methoxybenzene, 1- (2- (6- (3,4-dihydroxycinnamoyl) -3- Rhamnosyl)
  • Astringents can be added to the present invention.
  • astringents include succinic acid, allantoin, zinc chloride, zinc sulfate, zinc oxide, calamine, zinc p-phenolsulfonate, potassium aluminum sulfate, resorcin, ferric chloride, tannins (tannic acid, hammelitannin Acer tannin, tetragalloyl glucose, pentagalloyl glucose, hexagalloyl glucose, heptagalloyl glucose, octagalloyl glucose, nonagaroyl glucose, decagalloyl glucose, undecagalloyl glucose, dodecagalloyl glucose, etc.
  • Gallotannins telimaglandin I, telimaglandin II, casarictin, peduncraggin, geraniin, isoturkevin, granatin A, granatin B, ketulinic acid, keblagic acid, casuarinin, nuphalin, procyanidin B-2 Ellagitannins such as thiacinensin A and thiacinensin B), red grape grape extract, azuki bean (red bean) extract,retea extract, nettle extract, cascarilla extract, kapoch extract, guarana extract, ezo strawberry extract, Dutch strawberry extract, shrimp strawberry extract , Japanese White Strawberry Extract, Maple Strawberry Extract, European Raspberry Extract, Kidachi Aloe Extract, Hawthorn Extract, Coustella Hakka Extract, Cowberry (Etsutachibana) Extract, Cola Vera Extract, Sugarcane Extract, Chinese Red Flower Extract, Honeysuckle Extract Q) Extract, Japanese larch extract, Elder extract, Dandelion
  • Anti-inflammatory agent / interleukin production inhibitor / histamine release inhibitor can be added to the present invention.
  • anti-inflammatory agents, interleukin production inhibitors and histamine release inhibitors include quinolinone derivatives, dibenzooxepin derivatives, thiotroposin, phthalimide derivatives, flurbiprofen, felbinac, bufexamac, suprofen, 1,4-diphenylpropyl Piperazine derivatives, carxin compounds, chromanol glycosides (2- ( ⁇ -D-glucopyranosyl) methyl-2,5,7,8-tetramethylchroman-6-ol), ictamol, indomethacin, kaolin, diphenhydramine hydrochloride, d- Camphor, DL-camphor, salicylic acid, sodium salicylate, methyl salicylate, acetylsalicylic acid, hydrocor
  • Anti-seborrheic agent can be added to the present invention.
  • Specific examples of the antiseborrheic agent include chroman derivatives, pyridoxine or salts thereof and derivatives thereof, pyridoxal or salts thereof and derivatives thereof, pyridoxamine or salts thereof and derivatives thereof, sulfur, Asa extract, (Continuous) extract, Dutch mustard (watercress) extract, valerian extract (valerian root) extract, clematis extract, bear sebacekis, saveso extract, rosewood extract, horse chestnut extract, soybean (soybean) extract, milkflower extract (marigold) extract, Chinese yam Examples include extracts, yam extract, nosenhalen extract, dandelion poppy (sect winter flower, winter winter leaf) extract, japonica extract, giant kelp extract, hijirimen extract, primrose extract, haius banori extract and the like.
  • antibacterial agent can be added to the present invention.
  • antibacterial agents include acrinol, sulfur, calcium gluconate, chlorhexidine gluconate, sulfamine, mercurochrome, lactoferrin or hydrolyzate thereof, alkyldiaminoethylglycine chloride solution, triclosan, sodium hypochlorite, chloramine T, salashi powder , Iodine compounds, iodoform, 1-alkylcarbapenem compounds, N-substituted azepane derivatives or salts thereof, sorbic acid or salts thereof, propionic acid or salts thereof, salicylic acid or salts thereof, dehydroacetic acid, parahydroxybenzoic acid esters, 2 -Keto-3-deoxyoctanoic acid fatty acid esters, inositol deoxy derivatives (such as quercitol), inositol unsaturated derivatives (such as chond
  • Blood flow promoter / vascular stimulator A blood flow promoter / vascular stimulator can be added to the present invention.
  • blood flow promoters and vascular stimulants include tocopherol or salts thereof and derivatives thereof, tocotrienol or salts thereof and derivatives thereof, cephalanthin, carpronium chloride, eugenol derivatives (acetyl eugenol, methyl eugenol, methyl isoeugenol, ethyl Eugenol, Ethylisoeugenol, Eugenol salicylate, etc.), Minoxidil, Pepper tincture, Nonyl acid vanillamide, Cantalis tincture, Pepper tincture, Pepper oil, L-menthol, Camphor, Benzyl nicotinate, Cinnarizine, Trazoline, Acetylcholine, Verapamil, Itamol , ⁇ -borneol, cyclandrate, nonyl acid wallenylamide, capsaicin
  • Antiandrogen Agent can be added to the present invention.
  • antiandrogens include follicular hormones (estrone, estradiol, ethinyl estradiol, etc.), isoflavones, oxendron, 4 ', 5,7-trihydroxy-8-prenylflavanone, 4', 5,7-trihydroxy-8 -Prenyl flavone, 3,3 ′, 4 ′, 5,7-pentahydroxy-8-prenyl flavone, nicorandil, cyclosporine and the like.
  • Structural proteolytic enzymes matrix metalloproteases such as elastase, collagenase, keratin protease, serine protease, integrin degrading enzyme, involucrin degrading enzyme, filaggrin degrading enzyme, laminin degrading enzyme, fibronectin degrading enzyme, proteoglycan degrading enzyme) activity inhibitor / structural protein Decomposition enzyme expression inhibitor
  • the present invention includes a matrix of structural proteolytic enzymes (elastase, collagenase, keratin protease, serine protease, integrin degrading enzyme, involucrin degrading enzyme, filaggrin degrading enzyme, laminin degrading enzyme, fibronectin degrading enzyme, proteoglycan degrading enzyme, etc.
  • a metalloprotease activity inhibitor / structural protease inhibitor can be added.
  • structural protease inhibitors include adenine derivatives (butanetriol-9-adenine and its phosphate adduct, propanediol-9-adenine and its phosphate adduct, Pentanetriol-9-adenine and its phosphate adducts), carbostyril derivatives or salts thereof, dicarboxylic acids (glutaric acid, adipic acid, pimelic acid, suberic acid, azelaic acid, sebacic acid, 1,9-nonamethylenedicarboxylic acid) Acid, 1,10-decamethylenedicarboxylic acid), rosmarinic acid, ursolic acid, oleanolic acid, hydroxamic acid derivative, esculetin derivative, anthocyanidins, nordihydroguaiaretech acid, 20-carboxy-16-hydroxy-21-nor- 5
  • Structural protein synthesis promoter A structural protein synthesis promoter can be added to the present invention.
  • the structural protein synthesis accelerator include ethanolamine derivatives, pentoxyphyllin, serine derivatives, geraniol, crocetin, methyl 4- (2-ethylhexyloxy) -2-hydroxybenzoate, 2-hydroxy-4- (3, 5,5-Trimethylhexyloxy) methyl benzoate, methyl 4-cyclohexylmethoxy-2-hydroxybenzoate, methyl 4- (2-cyclohexylethoxy) -2-hydroxybenzoate, 4- (3,7-dimethyl-6 -Octenyloxy) methyl 2-hydroxybenzoate, ethyl 3- (2-ethylhexyloxy) -5-hydroxybenzoate, methyl 5- (2-ethylhexyloxy) -2-hydroxybenzoate, 2-hydroxy-5 -(3,5,5-trimethylhexyloxy) methyl benzoate, methyl 5- (2-cycl
  • Mucopolysaccharide (hyaluronic acid, chondroitin sulfate, etc.) degrading enzyme inhibitor A mucopolysaccharide (hyaluronic acid, chondroitin sulfate, etc.) degrading enzyme inhibitor can be added to the present invention.
  • mucopolysaccharide (hyaluronic acid, chondroitin sulfate, etc.) degrading enzyme inhibitors include anacardic acid or derivatives thereof (6-pentadecatrienylsalicylic acid methyl ether, 6-pentadecatrienylsalicylic acid ethyl ether, 6-pentadeca Trienyl salicylic acid propyl ether, 6-pentadecatrienyl salicylic acid butyl ether, 6-pentadecatrienyl salicyl alcohol methyl ether, 6-pentadecatrienyl salicyl alcohol ethyl ether, 6-pentadecatrienyl salicyl alcohol propyl ether, 6- Pentadecatrienyl salicyl alcohol butyl ether, 6-pentadecatrienyl salicylaldehyde methyl ether, 6-pentadecatrienyl salicylaldehyde ethyl ether, 6-penta
  • Mucopolysaccharide synthesis promoter A mucopolysaccharide synthesis promoter can be added to the present invention.
  • Specific examples of mucopolysaccharide synthesis promoters include stilbene derivatives or salts thereof, morgin or salts thereof and derivatives thereof, N-acetylglucosamine, flax extract, cinnamon extract, mulberry extract, scotch extract, breadfruit extract, hirakotoji extract , Kotojitsu no Mata Extract, Yaleus Banori Extract, Kagiosu Banori Extract, Susius Banori Extract, Amiaosa Extract, Nagaaosa Extract, Hosobanosakamodoki Extract, Hirohatosakamodoki Extract, Yatsudegatatosakamodoki Extract, Kurotosakamodoki Examples include extract, Nezushinosakamodoki extract, Yusora extract, Etsukinotosakamodoki extract, Nankaitosakamodoki extract, Him
  • Intercellular lipid production promoter / intercellular lipid state improver can be added to the present invention.
  • Specific examples of intercellular adipogenesis promoters and intercellular lipid state improvers include phospholipids (phosphatidylethanol, phosphatidylcholine, phosphatidyltriethanolamine, phosphatidylserine, phosphatidic acid, phosphatidylglycerin, phosphatidylinositol, diacylphosphatidylcholine, diacylphosphatidylethanol Amine, diacylphosphatidylinositol, diacylphosphatidylserine, 1-cysteinylphosphatidic acid, 2-cysteinylphosphatidic acid, 1-glutathionylphosphatidic acid, 2-glutathionylphosphatidic acid, 1-azelaoylphosphatidic acid, 2- Azela oil phosphatidic acid, 1-hydroxyacy
  • Keratin solubilizer and stratum corneum peeling accelerator A keratolytic agent and stratum corneum peeling accelerator can be added to the present invention.
  • Specific examples of keratolytic agents and stratum corneum exfoliation accelerators include tropolone and its derivatives, resorcin, lactic acid, urea, salicylic acid, guanidine, ethanolamine, kikarasuuri (Gurone) extract, fenugreek extract, wisteria bean extract, and lentil extract. Chickpea extract, mungbean extract and the like.
  • Plasminogen activator antagonist inhibitor A plasminogen activator antagonist inhibitor can be added to the present invention.
  • Specific examples of the plasminogen activator antagonist inhibitor include rabbit daisy extract, canamgra extract, caladium extract, raspberry extract and the like.
  • Maillard reaction inhibitor A Maillard reaction inhibitor may be added to the present invention.
  • Maillard reaction inhibitors include aminoguanidines, flavanones (naringin, naringenin, liquiritin, liquiritigenin, digallic acid, luteoic acid, ellagic acid, glucogallin, tetralin, hamamelitannin, gallic tannin, tannic acid, geraniin, gallic acid Acid, galloyl gallic acid, ellagitannin, hexagalloyl glucose, heptagalloyl glucose, tetragalloyl glucose, trigalloyl glucose, pentagalloyl glucose, digalloyl quinic acid, trigalloyl quinic acid), 2-hydroxyphenylalkylamine derivative or its Salts, phenylpropenoic acid derivatives (3- [2,3-bis (methoxymethoxy) phenyl] propenoic acid,
  • Testosterone 5 ⁇ reductase activity inhibitor / hair papilla activator / hair growth promoter can be added to the present invention.
  • Specific examples of testosterone 5 ⁇ reductase activity inhibitor, hair papilla activator and hair growth promoter include ⁇ -amino- ⁇ -hydroxybutyric acid esters ( ⁇ -amino- ⁇ -hydroxybutyric acid methyl ester, ⁇ -amino- ⁇ - Hydroxybutyric acid ethyl ester, ⁇ -amino- ⁇ -hydroxybutyric acid propyl ester, ⁇ -amino- ⁇ -hydroxybutyric acid butyl ester, ⁇ -amino- ⁇ -hydroxybutyric acid ethylhexyl ester, ⁇ -amino- ⁇ -hydroxybutyric acid hexadecyl ester, ⁇ -amino- ⁇ -hydroxybutyric acid lauryl
  • proanthocyanidins (grape seed extract proanthocyanidins, apple-derived proanthocyanidins, pine-derived proanthocyanidins, purified procyanidin oligomers, procyanidin B-2, procyanidins B-2, procyanidins B-3 , Procyanidin C-1 etc.), arakashi extract, angelica extract, apricot , Hong Vietnamese extract, Ichiyakusou (one medicinal herb) extract, Enishida extract, psyllium (carlet child, car forerunner) extract, Psyllium extract Striped anteater extract, ginseng extract, scallop extract, cucumber nut extract, camphor extract, kubeba extract, buckthorn extract, oyster extract ) Extract, Sanekazura extract, Vinankazura extract, Matsubusa extract, Colombo extract, Condurango extract, Sasanqua extract, Sweet potato extract,
  • Hair matrix growth inhibitor / hair growth inhibitor may be added to the present invention.
  • Specific examples of hair matrix growth inhibitor / hair growth inhibitor include phthalazinones, benzoxazinones, phosphonic acid derivatives, cyproterone, 5 ⁇ -androstene-3 ⁇ , 17 ⁇ -diol, medroxyprogesterone, norethisterone, methanolone, and ichihatsu (First) extract, ash extract, kanto extract, sangiko extract, shiramo extract, sardine extract, scabbard fern extract, fritillary extract, honeysuckle extract, seaweed extract, oleum extract and the like.
  • Hair swelling agent / hair protecting agent can be added to the present invention.
  • Specific examples of the hair swelling agent / hair protecting agent include ethanolamine, urea, guanidine, silicones, blueberry extract, mango extract and the like.
  • Odorous substance eliminating agent An odorous substance eliminating agent can be added to the present invention.
  • Specific examples of the odorous substance eliminating agent include Inondo extract, Elemi extract, vanilla bins extract, pine extract and the like.
  • ingredients derived from plant-based materials used as additives to the present invention include Aokazura (Seifu Fuji) extract, Aotenma extract, Akasuguri extract, Aquine (crust) extract, Aguay Guasu extract, Abiyu extract, Abiurana extract, Yellow sapote extract, Ylang ylang extract, phalaenopsis extract, Uba tea extract, Ezo suzuran extract, Unboku extract, Elderberry extract, Ohisano Yuki extract, Sasa no Yuki extract, Toucan cactus extract, Omiya catechu extract, Onoelan extract, Crab extract, Karaya extract, Garyu extract, Kawaratake extract, Candelilla extract, Canna extract, Kidachi pepper extract, Kimenkaku extract, Cabb extract, Kiraja saponaria extract, Ginseca Extract, kimbsen extract, guapeba vermelha extract, kugenumaran
  • Dunaliella genus Dunaliella extract As specific examples of components derived from plant-based raw materials used as an additive to the present invention, Dunaliella genus Dunaliella extract, Kuwanomi genus Kuwanomimo extract, Volbox genus genus sunflower extract, Volbox genus Volbox extract, Palmera extract, Yotsumemo extract, Aomido genus Chrysanthemum extract, Vulgaris extract, Hibimidro spp.
  • Centipede extract Centipede spider extract, Centipede spider extract, Centipede extract, Centipede extract, Mucadeno Rhizobium arab extract, Hirakintoki spp.
  • Genus centipede extract Kintoki genus Nagakintoki extract, Kintoki sp.
  • Tsukasanoori Hanagakarimenia extract Honoho genus Hounoo extract, Higanage genus Hikagenoit extract, Hikagenoit genus Usuginu extract, Nikuho Nou genus Honoo extract, Venetian genus Venus nago extract, Susca venus Susca veni extract, Okaragusa genus Extract, Isomokka genus Isomokka extract, Kizino genus Kizino essence extract, Isodantsu genus Isodantsu extract, Atsunori genus Atsubanori extract Mizoogonori extract, Ogonori genus Beniogonori extract, Ogonori sp.
  • Ogonori genus Ogonori extract Ogonori genus Hitsuginu extract, Ogonori genus Ogonori extract, Ogonori Kubireogonori extract, Ogonori genus Mosaogonori extract, Ogonori Kinukabanori Extract, Namiiwatake Genus Namiitake Extract, Saimi Italiasa Extract, Saimi Saimi Extract, Lotus Jigusa Lotus Jigusa Extract, Black Haginus Black Hagininso Extract, Hishibukuro Hishibukuro Extract, Madaragusa Togemadara Extract Taoyagisou Taoyagisou Extract, Taoyagisou Hanasakura Extract, Fukutsunagi Fukutsunagi Extract, Fukutsunagi Suikokonori Extract, Hananoeda Hananoeda Extract, Hiratoyagi Hiratakaoyagi Extract, Darus Masagoshibari Extract, Durus Genus Anadrus Extract Weibusa spp., Buffalo genus
  • Egonori Egonori Extract Egonori Futogigi Extract, Saeda Saeda Extract, Chirimomiji Chirimomiji Extract, Habutaenori Extract, Coniferous Extract, Shiroshironori Extract, Usbeni Usbeni Extract, Hasujiginu Hasujiginu Extract, Nagakononohagi Nagisanoha Genus Sugiginu extract, Sugiginu genus Atsubasjiginu extract, Heius banori Kagious banori extract, Heius banori genus Yaleus banori extract, haius banori genus Suus banori extract, haius banori genus euus banus extract, genus genus genus genus Ayanishiki Extract, Ayaginu Ayaginu Extract, Dadia Enasariaia Extract, Shimadadia Isohagi Extract, Shimadadia Shimadadia Extract, Dajimodokida Prunus extract, Prunus crisp extract, Papaver
  • Hyodosigusa extract Hyodosigus genus Usbahiodo extract, Isomegusa genus Isomagusa extract, Suginasusa genus Sugenashigusa extract, Isobasho genus Isobasho extract, Ideyukogome genus Yuukogome extract, Ochimomoku genus Ochichimozoku Red Algae Extract, Shajiku Spider Extract, Shiratamamo Extract, Hoshitsurimo Hoshitsurimo Extract, Rikunotamnusu Extract, Flask Moth Hime Flask Moet Vinegar, bantams flask model extract, axle algae extract such as Toriperaekisu, include the yellow algae extract such as Chromophyton rosanoffii genus Chromophyton rosanoffii extract.
  • ingredients derived from animal materials used as an additive to the present invention include chicken crown extract, cow, pig or human placenta extract, pig or cow stomach, duodenum, intestine, spleen extract or degradation product thereof, cow Or porcine brain tissue extract, water-soluble collagen, collagen derivatives such as acylated collagen, collagen hydrolyzate, elastin, elastin hydrolyzate, water-soluble elastin derivative, keratin and its degradation product or derivatives thereof, silk protein and Degradation products thereof or derivatives thereof, porcine or bovine blood cell protein degradation products (globin peptides), cattle or porcine hemoglobin degradation products (hemin, hematin, heme, protoheme, heme iron, etc.), milk, casein and degradation products thereof Derivatives thereof, skim milk powder and degradation products thereof or derivatives thereof, lactoferrin or degradation products thereof, egg component, fish Decomposition products, nucleic acid-related substance (ribonucleic acid, deoxyribon
  • components derived from microbial raw materials used as additives for the present invention include yeast metabolites, yeast extract extracts, bacterial metabolites, bacterial extract extracts, metabolites such as fungi or mushrooms, actinomycetes metabolites, fungi Or extracts such as mushrooms, actinomycetes extract, natto metabolite, natto extract, rice fermented extract, rice bran (red potato, white birch) fermented extract, euglena extract or a decomposed product thereof, or their water-soluble derivatives, raw milk or defatted Examples include lactic acid fermented milk powder.
  • any part, cell, tissue, organ, metabolite, etc. derived from a transgenic or cell fusion can be used as the plant or animal or microbial raw material. Furthermore, it is obtained by culturing cells of any site, cell, tissue, organ, etc., for example, cultured cells derived from each tissue (cultures derived from animals such as fibroblasts, Langerhans cells, macrophages, epidermal cells, hepatocytes, etc.) Cell etc.), undifferentiated cell group, cell group in the middle of differentiation, and their metabolites can also be used.
  • ingredients of natural raw materials used as additives include inorganic salts (magnesium chloride, chloride) obtained from seawater such as deep seawater, for example, seawater salt, seawater dried product, Dead Sea or Atlantic Ocean or Pacific Ocean. Potassium etc.), sea mud or mud (Fango), for example, Italian mugo, German fungo, Eifel fungo, Kon fungo, etc.
  • Sea mud or mud (containing components: silicon dioxide, titanium dioxide, aluminum oxide, iron oxide, Manganese oxide, sodium oxide, potassium oxide, magnesium oxide, calcium oxide, strontium oxide, sodium, potassium, magnesium, calcium, chromium, iron, copper, nickel, zinc, lead, manganese, arsenic, water), saintoku stone, natural smectite , Bentonite, hectorite and the like.
  • Extracts derived from plant raw materials, animal raw materials, microbial raw materials, and other natural product raw materials used as additives are processed in a conventional manner according to the product type and form to be added (for example, pulverization, milling, Treatment, extraction, decomposition, fermentation or metabolic conversion by microorganisms, fractionation, purification, pressing, filtration, drying, pulverization, granulation, dissolution, sterilization, pH adjustment, deodorization, decolorization, etc. ) And arbitrarily select from various materials.
  • the solvent used for the extraction may be selected in consideration of the intended purpose and type of the product to be provided, or the processing performed later. Usually, water, methanol, ethanol, propyl alcohol, isopropyl alcohol, butanol, isopropanol are used.
  • Lower alcohol such as butanol or hydrous lower alcohol, propylene glycol, 1,3-butylene glycol, 1,2-butylene glycol, 1,4-butylene glycol, 1,5-pentanediol, 1,2-pentanediol, 1, 3-pentanediol, 1,4-pentanediol, 1,3,5-pentanetriol, 1,2-hexanediol, 1,5-hexanediol, 1,6-hexanediol, pentylene glycol, hexylene glycol, Polyhydric alcohols such as glycerin and polyethylene glycol (molecular weight 100 to 100,000) or hydrous polyhydric alcohols Various organic solvents such as acetone, ethyl acetate, diethyl ether, dimethyl ether, ethyl methyl ether, dioxane, acetonitrile, xylene, benzene, chloroform, carbon
  • the temperature of the solvent, the weight ratio of the solvent to the raw material, or the extraction time can be arbitrarily set for various raw materials and the solvent used.
  • the temperature of the solvent can be arbitrarily set in the range of ⁇ 4 ° C. to 100 ° C., but is preferably around 10 to 40 ° C. from the viewpoint of the stability of the components contained in the raw material.
  • the weight ratio of the solvent to the raw material can be arbitrarily set within the range of, for example, the raw material: solvent: 4: 1 to 1: 100, and the weight ratio of 1: 1 to 1:10 is particularly preferable.
  • Decomposition mainly includes decomposition by acid, decomposition by alkali, decomposition by enzyme, decomposition by high temperature and high pressure, and the like.
  • an acid for example, it is preferable to use an inorganic acid or an organic acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, formic acid, oxalic acid, hydrogen bromide, perchloric acid, and periodic acid.
  • an inorganic acid or an organic acid such as hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, acetic acid, formic acid, oxalic acid, hydrogen bromide, perchloric acid, and periodic acid.
  • alkali for example, sodium hydroxide, potassium hydroxide, calcium hydroxide, ammonium hydroxide, barium hydroxide, sodium carbonate, ammonium carbonate, calcium carbonate, magnesium hydroxide, sodium silicate, etc. are preferably used.
  • the concentration, reaction time, reaction temperature, and the like can be arbitrarily set for the target raw material.
  • an enzyme having a function of degrading proteins, polysaccharides, lipids or complexes thereof having an important function particularly with respect to cell structure, tissue structure, etc. for example, aminopeptidase, dipeptidase, dipeptide Peptidyl peptidase, tripeptidyl peptidase, carboxypeptidase, serine protease, trypsin, chymotrypsin, cysteine protease, thiol protease, papain, aspartate endopeptidase, metalloendopeptidase, bromelain, thermolysin, pronase, pepsin, rennin, pan Proteolytic enzymes (proteases) such as creatine, chymopapain, fic
  • Fermentation or metabolic conversion by microorganisms can be performed by inoculating and growing at least one kind of microorganism on a raw material as a substrate. Inoculation of microorganisms to the substrate can be done by adding microorganisms directly into the substrate, or by adsorbing them on a carrier such as alginic acid, polyvinyl, gelatin, etc., for example, in the form of fine beads composed of microorganisms and carrier. Further, it can be used by being fixed to the tube wall of the bioreactor.
  • a carrier such as alginic acid, polyvinyl, gelatin, etc.
  • Fermentation or metabolic conversion by microorganisms is not particularly defined as a microorganism to be used, but can generally be defined as microorganisms other than pathogenic microorganisms that exhibit significant toxicity to living bodies.
  • microorganisms to be used include microorganisms classified into yeasts: Aciculoconidium, Actonia, Aessosporon, Ambrosiozyma, Anthomyces, Apiotrichum, Arthroascus, Arxula, Ashbia, Ashbya, Asporomyces, Atelosaccharomyces Genus, Azymoprocandida, Babjevia, Ballistosporomyces, Bensingtonia, Blastobotrys, Blastodendrion, Blastoderma, Blastoschizomyces, Botryoascus, Botryozyma, Brettanomyces, Brettanomyces, Brettanomyces, Bruttalles Genus (Candida albicans,
  • Lactobacillus parakefiri Lactobacillus pentosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus rhamnosus, Lactobacillus sakei, Lactobacillus confusus, Lactobacillus viridescens, Lactobacillus johnsonii, Lactobacillus viscosus, Lactobacillus fermentatae, Lactobacillus acidophil-aerogenes, Lactobacillus leichmannii, Lactobacillus gasseri, Lactobacillus bifidus, Lactobacillus jugurt, Lactobacillus caucasicus, Lactobacillus arabinosus, Lactobacillus kunkeei, Lactobacillus nagelii, Lactobacillus fornicalis, Lactobacillus pentoaceticus, Lactobacillus xylosus, Lactobacillus minutus,
  • Rhizobium genus Rhizobium genus, Rhizomonas genus, Rhodobacter genus, Rhodococcus genus, Rhodopseudomonas genus, Rhodospirillum genus, Rothia genus, Rubrobacter genus, Ruegeria genus, Saccharomonospora genus, Saccharothrix genus, Serratia genus, Sinorhizobium genus spp., Streptoalloteichus spp., Streptococcus spp.
  • Streptococcus durans Streptococcus faecalis, Streptococcus faecium, Streptococcus bovis, Streptococcus equinus, Streptococcus mutans, Streptococcus salivarius, Streptococcus thermophilus, Streptococcus agalactiae, Streptococcus mitis, Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus lactis, Streptococc us dysgalactiae, Streptococcus sanguis, Streptococcus acidominimus, Streptococcus avium, Streptococcus uberis, Streptococcus cremoris, Streptococcus diacetilactis, etc.
  • Thermoplasma genus can be mentioned.
  • Microorganisms classified as non-yeast ascomycetes, basidiomycetes or incomplete fungi include Allomyces, Amoebidium, Amorphotheca, Arthroderma, Ascoidea, Ascobolus, Ascodesmis, Aspergillus, Aureobasidium, Botryosphaeria Botryotinia sp Genus, Dothidea genus, Endogone genus, Entomophthora genus, Emericella genus, Eupenicillium genus, Eurotium genus, Exobasidium genus, Gibberella genus, Glomus genus, Graphiola genus, Gymnoascus genus, Harpella genus, Helicomyces genus, Helvella genus, Hemicarpenteles genus, Hyphochytrium genus, Hyphochytrium Hypocrea, Laboulbenia, Labyrinthula, Leptos
  • microorganisms In fermentation or metabolic conversion by microorganisms, in addition to various raw materials such as plant-based materials, animal-based materials, and other natural product-based materials, the growth and metabolism of microorganisms are regulated or activated, and special biosynthesis or degradation pathways are induced. In order to achieve this, various compounds can be added to the raw material. For example, as a carbon source, sugar, ethane such as glucose, fructose, galactose, sucrose, maltose, mannose, lactose, glycerin, starch, etc.
  • sugar ethane such as glucose, fructose, galactose, sucrose, maltose, mannose, lactose, glycerin, starch, etc.
  • Hydrocarbons such as methane, propane, butane, formic acid, acetic acid, propionic acid, lauric acid, palmitic acid, fatty acids such as oleic acid, linoleic acid, linolenic acid, etc., nitrogen sources such as ammonium sulfate, ammonium hydrochloride, ammonium phosphate, etc. Ammonium salt, urea, uric acid, amino acids, etc.
  • the optimum temperature, oxygen supply amount, pH, pressure, etc. that affect the growth and metabolic activities of various microorganisms can be arbitrarily set according to the characteristics inherent to various microorganisms. Can be arbitrarily set within the range of 10 to 50 ° C., and the pH can be arbitrarily set within the range of 1 to 14.
  • fractionation or purification generally known techniques can be used as appropriate.
  • liquid chromatography ion exchange chromatography, ion exclusion chromatography, affinity chromatography, gel filtration chromatography, size exclusion chromatography, etc.
  • Chromatography hydrophilic adsorption chromatography, hydrophobic adsorption chromatography, ligand exchange chromatography, etc.
  • fractionation using a single column or multiple columns, dialysis with semipermeable membranes, crystallization and recrystallization of components. Examples thereof include crystallization, filter paper, membrane filter, ultrafilter, filtration using activated carbon, filter aid, etc., centrifugal separation and its application, fractional precipitation method, density gradient separation method such as density gradient sedimentation equilibrium method, and the like.
  • silicic anhydride magnesium silicate, talc, kaolin, bentonite, hectorite, natural or synthetic smectite, stevensite, mica, mica titanium, oxy Inorganic pigments such as bismuth chloride, zirconium oxide, magnesium oxide, zinc oxide, titanium oxide, calcium carbonate, magnesium carbonate, yellow iron oxide, bengara, black iron oxide, gunjou, chromium oxide, chromium hydroxide, carbon black, calamine, Hydrogen peroxide solution, sodium persulfate, ammonium persulfate, sodium perborate, urea peroxide, sodium percarbonate, sodium tripolyphosphate, sodium bromate, potassium bromate, sodium pyrophosphate, sodium orthophosphate , Silicic acid Thorium hydrogen peroxide adduct, sodium sulfate hydrogen peroxide adduct, sodium chloride hydrogen peroxide adduct,
  • Mineral oils such as fin, petrolatum, paraffin, ozokelide, ceresin, microcristan wax, lauric acid, myristic acid, palmitic acid, stearic acid, behenic acid, oleic acid, linoleic acid, linolenic acid, docosahexaenoic acid, eicosapentaenoic acid, 12 -Natural fatty acids such as hydroxy stearic acid, undecylenic acid, tall oil, lanolin fatty acid, synthetic fatty acids such as isononanoic acid, caproic acid, 2-ethylbutanoic acid, isopentanoic acid, 2-methylpentanoic acid, 2-ethylhexanoic acid, isopentanoic acid Fatty acids such as ethanol, isopyropanol, lauryl alcohol, cetanol, stearyl alcohol, oleyl alcohol, lanolin alcohol, cholesterol, phytosterol, phenoxy
  • alkali metal salts such as sodium salts and potassium salts, monoethanolamine salts, diethanolamine salts, triethanolamine salts, organic ammonium salts such as L-lysine salts and L-arginine salts, ammonium salts, etc.
  • Quaternary ammonium salts alkyl trimethyl ammonium chloride, cetyl ammonium chloride, cetyl ammonium bromide, lauryl ammonium chloride, lauryl ammonium bromide, stearyl ammonium chloride, stearyl ammonium bromide, cetyl dimethyl ammonium chloride, cetyl dimethyl methacrylate Ammonium, lauryl dimethyl ammonium chloride, stearyl dimethyl ammonium chloride, lauryl trimethyl ammonium chloride, lauryl trimethyl ammonium bromide, stearyl dimethyl cetyl ditallow dimethyl ammonium chloride, dicetyl ammonium chloride, dicetyl ammonium
  • Polyoxyethylene glycerin fatty acid ester polyoxyethylene glycerin monostearate, polyoxyethylene glycerin monoisostearate, polyoxyethylene glycerin triisostearate, etc.
  • sorbitan fatty acid ester sorbitan monolaurate, sorbitan monooleate, Sorbitan sesquioleate, sorbitan trioleate, sorbitan monopalmitate, sorbitan monostearate Sorbitan distearate, sorbitan dioleate, sorbitan monopalmitate, sorbitan tristearate, sorbitan trioleate, diglycerine sorbitan penta-2-ethylhexylate, diglycerin sorbitan tetra-2-ethylhexylate, polyoxyethylene monooleate Sorbitan, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monopalmitate, polyoxyethylene sorbitan monoole
  • Test 1 Kinesin inhibitory action test The inventor decided to evaluate the kinesin inhibitory action of human epidermis-derived pigment cells.
  • Test method and evaluation method Each sample was added after culturing human epidermis-derived pigment cells in a culture dish. After 72 hours, cells were harvested with phosphate buffered saline (PBS). The collected cells were lysed with RIPA buffer (50 mM Tris-HCl, pH 7.5, 1% NP-40, 150 mM NaCl, 0.1% SDS, 0.5% deoxycholate and 1 mM PMSF). Boiled for a minute. Subsequently, electrophoresis was performed by SDS-10% PAGE, and transferred to a PVDF membrane (BioRad, Hercules, CA).
  • PBS phosphate buffered saline
  • the PVDF membrane was blocked with 0.05% Tween 20 and 5% (w / v) non-fat milk overnight, and then reacted by adding a kinesin antibody. After washing the PVDF membrane, an anti-mouse IgG antibody (Amersham Pharmacia Biotech) was reacted, and the expression level was detected with an ECL detection reagent (Amersham Pharmacia Biotech). From the photographed photograph, the expression level of kinesin was calculated by image analysis, and the inhibition rate relative to the control group was determined. The results are shown in FIG.
  • sample The samples of the kinesin inhibitory action test were the luteolin of the present invention, the glycoside of luteolin “Luteolin-7-O-galactoside, luteolin-7-O-galactoside-4 ′, luteolin-4′-O-glucuronide, luteolin. 5 ⁇ M of “5-O-glucuronide, luteolin-7-O-glucuronide, luteolin-4′-O-glucoside, luteolin-7-O-glucoside” (ChemFaces) was added for the test.
  • Test 2 Use effect test The effect at the time of actually using the emulsion of this invention was examined.
  • the usage test is a panel of 20 women aged 30 to 60 who suffer from pigmentation, and every day, morning and night, apply the appropriate amount of the emulsion of Formulation 1 to the face for 3 months. It was done by doing.
  • excluding the luteolin of this invention or its glycoside from the emulsion by the same method was used for the control.
  • the evaluation method is based on the following criteria, and the results are as shown in Table 1.
  • the numerical values in the table represent the number of people. No one complained of skin abnormalities during the period of use.
  • luteolin of the present invention or a glycoside thereof (luteolin-7-O-galactoside, luteolin-7-O-galactoside-4 ′, luteolin-4′-O-glucuronide, luteolin-5-O-glucuronide) , Luteolin-7-O-glucuronide, luteolin-4'-O-glucoside, luteolin-7-O-glucoside) significantly inhibits spots and freckles and also suppresses pigmentation did it.
  • the present invention relates to a specific substance, luteolin or a glycoside thereof (luteolin-7-O-galactoside, luteolin-7-O-galactoside-4 ′, luteolin-4′-O-glucuronide, luteolin-5-O-glucuronide , Luteolin-7-O-glucuronide, luteolin-4′-O-glucoside, luteolin-7-O-glucoside) as an active ingredient, a kinesin inhibitor or pigmentation inhibitor.
  • various compositions (pharmaceutical composition, food / beverage composition, cosmetic composition) containing a kinesin inhibitor or a pigmentation inhibitor can be provided.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)

Abstract

L'invention concerne : un nouvel inhibiteur de kinésine utile ; et une composition utilisée pour atténuer ou prévenir différents types de symptômes de la pigmentation, notamment les éphélides ou taches de rousseur. L'invention concerne également un inhibiteur de kinésine ou un agent empêchant la pigmentation, chacun d'eux contenant, en tant que principe actif, une substance spécifique, c'est-à-dire la lutéoline ou son glucoside (par exemple les composés lutéoline-7-O-galactoside, lutéoline-7-O-galactoside-4', lutéoline-4'-O-glucuronide, lutéoline-5-O-glucuronide, lutéoline-7-O-glucuronide, lutéoline-4'-O-glucoside, lutéoline-7-O-glucoside). L'invention concerne également différentes compositions (composition pharmaceutique, composition alimentaire ou boisson, composition cosmétique) contenant chacune un inhibiteur de kinésine ou un agent empêchant la pigmentation.
PCT/JP2014/068526 2014-01-28 2014-07-11 Utilisation d'un inhibiteur de kinésine contenant de la lutéoline ou son glucoside comme principe actif WO2015114855A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014-013309 2014-01-28
JP2014013309A JP2015140308A (ja) 2014-01-28 2014-01-28 ルテオリン又はその配糖体を有効成分とするキネシン抑制剤

Publications (1)

Publication Number Publication Date
WO2015114855A1 true WO2015114855A1 (fr) 2015-08-06

Family

ID=53756458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/068526 WO2015114855A1 (fr) 2014-01-28 2014-07-11 Utilisation d'un inhibiteur de kinésine contenant de la lutéoline ou son glucoside comme principe actif

Country Status (2)

Country Link
JP (1) JP2015140308A (fr)
WO (1) WO2015114855A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112843123A (zh) * 2019-11-12 2021-05-28 中国医学科学院药物研究所 福建青冈提取物在制备治疗胃相关疾病药物中的应用
CN113100240A (zh) * 2021-03-11 2021-07-13 湖北省烟草科学研究院 一种诱导茄科作物抗青枯病的诱抗剂及其制备方法和应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6515714B2 (ja) 2015-07-14 2019-05-22 三菱電機株式会社 トランジスタ
KR102182919B1 (ko) * 2018-12-28 2020-11-25 경희대학교 산학협력단 운카리나 스텔루리페라 추출물을 유효성분으로 포함하는 노화방지 또는 주름개선용 조성물
JP6786193B1 (ja) * 2019-02-01 2020-11-18 一丸ファルコス株式会社 細胞外ａｔｐ濃度上昇抑制剤
WO2021143006A1 (fr) * 2020-01-13 2021-07-22 江苏大学 Planococcus et procédé d'amélioration de la qualité de fermentation de sauce de poisson à faible teneur en sel l'utilisant
CN115887330A (zh) * 2022-12-29 2023-04-04 北京元知禾生物科技有限公司 洋甘菊提取产品及其制备方法和应用

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11246426A (ja) * 1998-02-26 1999-09-14 Ogawa Koryo Co Ltd 高脂血症治療剤およびこれを含有する食品組成物
JP2000086510A (ja) * 1998-09-16 2000-03-28 Oriza Yuka Kk ヒスタミン遊離抑制剤
JP2003201208A (ja) * 2001-12-28 2003-07-18 Ichimaru Pharcos Co Ltd 化粧料組成物
JP2012171906A (ja) * 2011-02-21 2012-09-10 Oriza Yuka Kk 皮膚光老化予防剤
JP2012219093A (ja) * 2011-04-14 2012-11-12 Ichimaru Pharcos Co Ltd キネシン抑制剤
JP2014132224A (ja) * 2013-01-04 2014-07-17 Nagase & Co Ltd 皮膚色素沈着抑制物質のスクリーニング方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11246426A (ja) * 1998-02-26 1999-09-14 Ogawa Koryo Co Ltd 高脂血症治療剤およびこれを含有する食品組成物
JP2000086510A (ja) * 1998-09-16 2000-03-28 Oriza Yuka Kk ヒスタミン遊離抑制剤
JP2003201208A (ja) * 2001-12-28 2003-07-18 Ichimaru Pharcos Co Ltd 化粧料組成物
JP2012171906A (ja) * 2011-02-21 2012-09-10 Oriza Yuka Kk 皮膚光老化予防剤
JP2012219093A (ja) * 2011-04-14 2012-11-12 Ichimaru Pharcos Co Ltd キネシン抑制剤
JP2014132224A (ja) * 2013-01-04 2014-07-17 Nagase & Co Ltd 皮膚色素沈着抑制物質のスクリーニング方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHOI, M.Y. ET AL.: "Whitening Activity of Luteolin Related to the Inhibition of cAMP Pathway in a-MSH-stimulated B16 Melanoma Cells", ARCH PHARM RES, vol. 31, no. 9, 2008, pages 1166 - 1171, XP055217229 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112843123A (zh) * 2019-11-12 2021-05-28 中国医学科学院药物研究所 福建青冈提取物在制备治疗胃相关疾病药物中的应用
CN112843123B (zh) * 2019-11-12 2022-11-04 中国医学科学院药物研究所 福建青冈提取物在制备治疗胃相关疾病药物中的应用
CN113100240A (zh) * 2021-03-11 2021-07-13 湖北省烟草科学研究院 一种诱导茄科作物抗青枯病的诱抗剂及其制备方法和应用
CN113100240B (zh) * 2021-03-11 2022-06-07 湖北省烟草科学研究院 一种诱导茄科作物抗青枯病的诱抗剂及其制备方法和应用

Also Published As

Publication number Publication date
JP2015140308A (ja) 2015-08-03

Similar Documents

Publication Publication Date Title
JP6029284B2 (ja) キネシン抑制剤
JP5441368B2 (ja) メラニン生成抑制剤
WO2015114855A1 (fr) Utilisation d'un inhibiteur de kinésine contenant de la lutéoline ou son glucoside comme principe actif
JP2006327988A (ja) 美白剤及び美白用皮膚外用剤
JP6324458B2 (ja) キネシン抑制剤
JP2015063479A (ja) 植物抽出物によるカスパーゼ−１４発現誘導剤
JP2013095667A (ja) アクアポリン産生増強製剤
JP2014019683A (ja) メラニン含有ケラチノサイト分裂促進剤
JP6268148B2 (ja) 角質層を透明にする化粧料
JP2010241777A (ja) アクアポリン産生増強製剤及びその方法
JP5878714B2 (ja) リンパ管腔形成促進剤
JP2014114241A (ja) プロオピオメラノコルチン発現抑制剤
JP5955640B2 (ja) メラニン生成抑制剤又は美白化粧料
JP2007314483A (ja) 外用製剤並びに外用製剤の製造方法
JP5756326B2 (ja) キネシン抑制剤
JP2015101571A (ja) 絹の亜臨界水処理物の製造法及び化粧料組成物
JP2010083838A (ja) アディポネクチン産生促進剤
JP6025684B2 (ja) フェニルエチルアミン誘導体又はシネフリンによるカスパーゼ−１４発現誘導剤
JP2013087058A (ja) アクアポリン産生増強製剤
JP2013087057A (ja) アクアポリン産生増強製剤
JP6132456B2 (ja) キネシン抑制剤
JP6130989B2 (ja) キネシン抑制剤
JP2005200334A (ja) 皮膚老化又は皮膚疾患の予防又は改善方法
JP2010047483A (ja) コラーゲンゲル収縮促進剤
JP2014208596A (ja) 角質層を透明にする化粧料

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14880502

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14880502

Country of ref document: EP

Kind code of ref document: A1